ARQ-151 Emerging Drug Insight and Market Forecast - 2032

“ARQ-151 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about ARQ-151 for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the ARQ-151 for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the ARQ-151 for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ARQ-151 market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

Topical Roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases the production of anti-inflammatory mediators. It has been implicated in a wide range of inflammatory diseases, including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD).

In July 2018, the company executed a licensing agreement with AstraZeneca for exclusive worldwide rights to Roflumilast used as the active pharmaceutical ingredient in ARQ-151 and ARQ-154 as a topical product in humans solely for dermatological indications, including AD.

In September 2020, the company announced the acceleration of ARQ-151 into Phase III trials to treat adolescents and adults with AD following the end of Phase II meeting with the FDA. The company initiated pivotal Phase III trials in patients with atopic dermatitis (INTEGUMENT-1 and INTEGUMENT-2) in January 2021.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ARQ-151 description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.
• Elaborated details on ARQ-151 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ARQ-151 research and development activities in atopic dermatitis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ARQ-151.
• The report contains forecasted sales of for atopic dermatitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.
• The report also features the SWOT analysis with analyst views for ARQ-151 in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ARQ-151 Analytical Perspective

In-depth ARQ-151 Market Assessment

This report provides a detailed market assessment of ARQ-151 for atopic dermatitis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

ARQ-151 Clinical Assessment

The report provides the clinical trials information of ARQ-151 for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARQ-151 dominance.
• Other emerging products for atopic dermatitis are expected to give tough market competition to ARQ-151 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARQ-151 in atopic dermatitis.
• This in-depth analysis of the forecasted sales data of ARQ-151 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ARQ-151 in atopic dermatitis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of ARQ-151?
• What is the clinical trial status of the study related to ARQ-151 in atopic dermatitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARQ-151 development?
• What are the key designations that have been granted to ARQ-151 for atopic dermatitis?
• What is the forecasted market scenario of ARQ-151 for atopic dermatitis?
• What are the forecasted sales of ARQ-151 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ARQ-151 for atopic dermatitis?
• Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?

This product will be delivered within 2 business days.